Covestor LTD Vertex Pharmaceuticals Inc Transaction History

Covestor LTD

$160 Million
Q3 2024

A detailed history of Covestor LTD transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Covestor LTD holds 684 shares of VRTX stock, worth $280,139. This represents 0.2% of its overall portfolio holdings.

Number of Shares

684

Previous 706 3.12%

Holding current value

$280,139

Previous $331,000 3.93%

% of portfolio

0.2%

Previous 0.21%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	SELL	$460.0 - $505.78 $10,120 - $11,127	-22 Reduced 3.12%	684 $318,000
Q2 2024 Aug 09, 2024	BUY	$392.81 - $485.53 $117,057 - $144,687	298 Added 73.04%	706 $331,000
Q1 2024 May 10, 2024	SELL	$407.69 - $446.08 $128,422 - $140,515	-315 Reduced 43.57%	408 $171,000
Q4 2023 Feb 09, 2024	SELL	$343.0 - $410.68 $39,788 - $47,638	-116 Reduced 13.83%	723 $295,000
Q3 2023 Nov 13, 2023	SELL	$338.18 - $362.46 $39,905 - $42,770	-118 Reduced 12.33%	839 $292,000
Q2 2023 Aug 11, 2023	SELL	$314.42 - $351.91 $23,581 - $26,393	-75 Reduced 7.27%	957 $337,000
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $12,462 - $14,216	44 Added 4.45%	1,032 $326,000
Q4 2022 Feb 13, 2023	BUY	$285.76 - $321.48 $17,431 - $19,610	61 Added 6.58%	988 $285,000
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $26,835 - $29,941	98 Added 11.82%	927 $268,000
Q2 2022 Aug 10, 2022	SELL	$234.96 - $292.55 $53,100 - $66,116	-226 Reduced 21.42%	829 $234,000
Q1 2022 May 13, 2022	BUY	$221.42 - $260.97 $35,205 - $41,494	159 Added 17.75%	1,055 $275,000
Q4 2021 Feb 10, 2022	BUY	$177.01 - $223.45 $158,600 - $200,211	896 New	896 $197,000

Others Institutions Holding VRTX

# of Institutions

1,725

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Covestor LTD, based on Form 13F filings with the SEC.

News

Stay updated on Covestor LTD with notifications on news.

Account